论文部分内容阅读
长春瑞滨通过抑制微管聚合,使细胞分裂停止于有丝分裂中期,从而发挥抗癌作用[1]。临床上长春瑞滨是晚期非小细胞肺癌(NSCLC)的一线治疗药物,也用于转移性乳腺癌、难治性淋巴瘤、卵巢癌及头颈部肿瘤的治疗,主要剂量限制性不良反应为较强的神经毒性、骨髓抑制、白细胞下降、胃肠道反应及外周神经毒性[2-3],这使得患者难以长期坚持用药,从而限制了药物疗效的发挥。
Vinorelbine inhibits microtubule polymerization and stops cell division at the metaphase, thereby exerting an anti-cancer effect [1]. Clinically, vinorelbine is a first-line treatment for advanced non-small cell lung cancer (NSCLC) and is also used in the treatment of metastatic breast cancer, refractory lymphoma, ovarian cancer and head and neck cancer. The main dose-limiting adverse effects are Strong neurotoxicity, bone marrow suppression, leukopenia, gastrointestinal reactions and peripheral neurotoxicity [2-3], which makes it difficult for patients to adhere to long-term medication, thus limiting the efficacy of the drug.